

## Exogenous lipoid pneumonia FOLLOWING lactulose intake in an infant. Clinical case.

**Comment [H1]:** Authors should be sure that the case did not consume paraffin oil also for treatment of constipation. As lactulose is a sugar derived from milk sugar lactose and is completely different from paraffin oil derived from kerosene which is known to cause lipoid pneumonia. On the other hand, Lactulose is not known to cause lipoid pneumonia.

### Abstract

Exogenous lipoid pneumonia is a rare condition in common pediatric practice. Its clinical presentation is non-specific. Delay in diagnosis and treatment exposes infants to chronic respiratory failure. We report the observation of a 2-month-old infant with respiratory signs that drag on. The imaging showed several negative density pulmonary ~~opa~~city opacities. Foam cells ~~was~~ were isolated on sputum cytological study. Taking lactulose for constipation suggested Exogenous lipoid pneumonia. The aim of herein observation is to draw attention to mineral oil administration drug risks in infants especially if they are at risk.

**Keywords:** Exogenous lipoid pneumonia-Lactulose-Infant.

### Introduction

Exogenous lipoid pneumonia (ELP) is a rare condition in routine paediatric practice. Its clinical presentation is non-specific. Delayed diagnosis and treatment expose the patient to respiratory complications that can lead to chronic respiratory failure. The benefit of

Our ~~objective~~ ~~comment~~ is to draw attention to the risks of administering mineral oil-based medicines to young children, especially if they are at risk.

#### Case presentation :

G.M., a 2-month-

old infant, was admitted to hospital with dyspnea, malaise, cough and tachycardia, which had been evolving for 20 days in a context of apyrexia. This symptomatology did not seem to respond to the treatments administered during several consultations. The patient was born of a well-monitored pregnancy carried to term. There were no incidents during the neonatal period. She has had regurgitation since birth, with untreated breastfeeding and bouts of cyanotic coughing during feedings. Her constipation was treated orally with kerosene oil. Examination revealed an infant in good general condition, weighing 5 kg for a height of 58 cm, afebrile, tachypneic at 70 cycles/min, with no signs of struggle and snoring, especially on the right side. There were no signs of heart failure. Biological workup does not suggest bacterial infection. The abdomen is soft and there is no hepatosplenomegaly. The rest of the examination was normal. No signs of bacterial infection (white blood cell count 8800  $\mu\text{c}/\text{mm}^3$ , CRP 13  $\text{mg}/\text{mmol}/\text{l}$ ).

A frontal chest X-ray and chest CT scan were performed (figs. 1 and 2). The frontal chest X-ray showed multiple alveolar-type opacities (blurred boundaries with bronchogram), one in the right upper lobe and bilateral para-hilar. Chest CT revealed several bilateral parenchymal para-hilar ground-glass opacities, heterogeneous and containing a few areas of negative density.

**Comment [H2]:** If authors mean lactulose here it is wrong as lactulose is not a kerosene oil.



**Figure 1** Front chest X-ray shows multiple alveolar opacities (blurred boundaries with bronchogram), one in the right upper lobe and bilateral para-hilar.



**Figure 2** Chest CT scan reveals several bilateral, heterogeneous, intra-parenchymal para-hilar ground-glass opacities, with some areas of negative density.



**Figure 3** Chest CT parenchymal opacities with negative density between -154 and -122HU.

Given the notion of vomiting since birth, we performed PH-metry, which was not in favor of gastroesophageal reflux (acid time (PH<4) less than 2% on a 24-hour recording, gastric tube controlled taking meals into account). The notion of taking kerosene oil to treat constipation prompted us to explore the possibility of exogenous or oily inhalation pneumonitis or lipoid pneumonia. To confirm the diagnosis, we reassessed the density of the parenchymal opacities, which were between -154 and -122 HU and therefore lipidic in nature. We were able to demonstrate the presence of lipid foam cells in the sputum with multiple sessions of fine aspirations. Our patient was treated symptomatically with respiratory physiotherapy and oxygen therapy according to hemoglobin oxygen saturation, and prednisone 2 mg/Kg/d for 2 weeks. Clinical evolution was favorable after 10 days of hospitalization, and radiological clearance was obtained after 3 months.

### Discussion

Lipid or lipoid pneumonitis comprises two entities: the exogenous form, also known as exogenous lipoid pneumonitis (ELP) or oily pneumonitis, and the endogenous form, known as endogenous lipoid pneumonitis or cholesterol pneumonitis. The latter is secondary to the release of lipids normally contained in lung tissue destroyed upstream of an obstructive bronchial lesion or by suppuration. More rarely, endogenous lipoid pneumopathy results from fat embolism, alveolar proteinosis or lipid storage disorders. [\(reference\)](#)

**PLEELP**, a rare condition, is most often the result of repeated micro-inhalations of mineral oil. Lung damage varies according to the type of oil (mineral, vegetable or animal), the quantity and duration of intoxication [1]. The acute form corresponds to significant inhalation, and although it can lead to acute respiratory failure, it is often unrecognized due to the non-specific nature of the symptoms and its rarity. The chronic form

**Comment [H3]:** ELP should be used as authors mean exogenous lipoid pneumonia. ELP is abbreviation for other diseases as protein losing enteropathy or panlobular emphysema.

correspond to repeated, pauci-symptomatic micro-

inhalations, leading to fibrosis lesions associated with a granulomatous "paraffinoma" reaction [2].

From a pathophysiological standpoint, mineral oil is a pure, inert hydrocarbon. Its tracheobronchial penetration inhibits the cough reflex and the action of vibratile cilia. At the alveolar level, mineral oil is responsible for an intra-alveolar infiltrate of macrophages associated with an acute inflammatory reaction. The oil is then emulsified and phagocytized, leading to vacuolation of the macrophages, which migrate to the interstitium, forming a multinucleated, vacuolated giant cell granuloma. In the later stages, the disease progresses to fibrosis [3].

In the majority of cases, PLE-ELP results from the administration of mineral oil given orally to treat constipation, or from the inhalation of milk [4]. Rabah R et al [56], report the occurrence of PLE-ELP after rectal administration of mineral oil in a patient with Hirschsprung's disease via an embolism mechanism. De la Rocha et al [67] reported 1 case of ELP following accidental aspiration of mineral oil in a 13-month-old infant who required oxygen therapy

for a period of five months. Furthermore, vigorous opposition by infants to the oral administration of mineral oil exposes them to aspiration [6]. Patients with motor delay and/or associated swallowing disorders are particularly at risk of developing PLEELP [7].

The clinical presentation of PLE-ELP is non-specific and depends on the patient's age, the volume of oil aspirated, the presence or absence of risk factors and the chronicity of aspiration. The latent nature of the disease is classic, hence the importance of the anamnesis in authenticating and characterizing exposure to the lipid product and in identifying risk factors.

In the series by Hari P. R. Bandla et al, (8) 41% of cases were discovered incidentally, of which 25%

remained clinically latent. Cough, chest pain, fever, weight loss and crepitus rales were the most frequently observed clinical symptoms. In another study, the same percentage of cases was found to be latent.

asymptomatic in 41% of cases, fever in 39%, weight loss in 34%, cough in 64%, dyspnoea in 50%, chest pain in 21%, haemoptysis in 13% and, on physical examination, 54% of crackling rales [8]. These patients are at risk of non-tuberculous mycobacterial infections, which can be revealing, as lipids increase the growth of these organisms and prevent their phagocytosis by macrophages [9,10,19,20].

Standard radiographic signs are non-specific and variable, ranging from a peripheral, bilateral lobar alveolar syndrome affecting mainly the lower and posterior lobes, giving a "ground-glass" appearance, to an interstitial and nodular or even pseudotumoral syndrome. "paraffinoma". The appearance of a bilateral excavated nodule confusing with Wegener's granuloma has been reported, following inhalation of kerosene oil. Chest CT is highly suggestive of the lipid nature of opacities found on standard radiography, as it measures negative density (between -150 and -30 Hounsfield units) within these lesions [11,12,21]. It can also show thickening of the interlobular septa, areas of ground glass or the association of small reticulated opacities within areas of ground glass known as "crazy-paving". CT can also be used to determine the exact number of lesions, their location and size, and to monitor their evolution. Some authors also suggest comparing this density with that of subcutaneous adipose tissue, whose density is comparable [13]. Lee JS et al [14,17] analyzed high-resolution CT findings in 25 patients, according to the presence or absence of predisposing factors, and their route and duration of inhalation of a mineral oil "squalene" derived from shark liver. Results were classified into three patterns: diffuse ground-glass opacity, consolidation, and interstitial abnormalities. The ground-glass appearance was mostly found in patients with predisposing factors and after nasal instillation in large quantities. The appearance of consolidation was found mainly in patients with no predisposing factors and taking squalene for several months. Patients with

interstitial syndrome all show "squalene" uptake beyond 1 year. A similar study was carried out by BARON-~~Baronet~~ al(15) on 15 cases of PLE-ELP, the aim of which was to distinguish between acute and chronic forms of PLE on the basis of radiological presentation. He concluded that the features favouring acute forms were the presence of a pleural reaction and enhancement on standard imaging and chest CT ( $p < 0.05$ ). The presence of masses was synonymous

with chronic forms ( $p < 0.05$ ). Thoracic MRI can confirm the diagnosis on the basis of fat saturation on T1-weighted sequences. Fat suppression sequences show a decrease in lesion signal, enabling differentiation from hemorrhagic infiltrates. In practice, analysis of radiological images (standard radiography and thoracic CT or even MRI) in the light of anamnesic data (exposure to oil with or without risk factors), and of the evolution (reversibility or not) makes it possible to link clinical symptomatology to PLE-ELP and to outline a prognosis.

Cytochemical analysis of bronchoalveolar lavage fluid can, if necessary, confirm PLE-ELP. Bronchoscopy with examination of the bronchoalveolar lavage fluid enables the diagnosis of PLE-ELP to be made, as lipid globules are found on the surface of the fluid and lipid-laden macrophages are present, with measurement of the load index [15]. Bronchoscopy has the added advantage of exploring the airways to rule out other causes of dragging pneumonia that could be confused with PLE-ELP. On the other hand, invasive investigations such as needle biopsy or thoracotomy are not justified [16] if the clinical history and thoracic CT scan are suggestive enough, unless it is a granuloma or paraffinoma with signs of activity.

Treatment of PLE-ELP in children is generally symptomatic, with resolution of symptoms and radiographic abnormalities within months of cessation of exposure [22,23,24].

In cases of diffuse lung damage, high-dose prednisone

[17] and therapeutic lung lavage may be considered [18]. It is clear that in this

that the prevention of another episode of pneumonia should involve not self-medication, consulting a specialist in the event of worrying or lingering symptoms, and eliminating lactulose as a first-line treatment for constipation [24].

### Conclusion

~~PLEELP~~ should be considered in the presence of exposure to ~~apetroleum product~~ lactulose, especially if there are risk factors and radio-clinical discordance. The administration of ~~mineral~~ ~~oil~~ lactulose for the treatment of chronic constipation should be approached with caution, and preferably avoided in infants resistant to its administration, and in children with or without mental retardation and swallowing disorders.

**Comment [H4]:** Authors should be sure again from patient's history if she used only lactulose or also used liquid paraffin for her constipation or even the pneumonia resulted from her regurgitation of food and milk and correct the title and the conclusion according to that history. Whatever the cause of pneumonia in this case, it is an interesting case.

UNDER PEER REVIEW

## References

- [1] Godwin JD, Müller NL, Takasugi JE. Pulmonary alveolar proteinosis: CT findings. *Radiology*. 1988 Dec; 169(3):609-13.
- [2] Gondouin A, Manzoni PH, Ranfaing E, et al. Exogenous lipid pneumonia: a retrospective multicenter study of 44 cases in France. *Eur Respir J*. 1996 Jul; 9(7): 1463-9.
- [3] Wheeler PS, Stitik FP, Hutchins GM, Klinefelter HF, Siegelman SS. Diagnosis of lipid pneumonia by computed tomography. *JAMA*. 1981 Jan 2; 245(1):65-6.
- [4] Franquet T, Giménez A, Bordes R, Rodríguez-Arias JM, Castella J. The crazy-paving pattern in exogenous lipid pneumonia: CT-pathologic correlation. *AJR Am J Roentgenol*. 1998 Feb; 170(2): 315-7.
- [5] Annobil SH, Ogunbiyi AO, Benjamin B. Chest radiographic findings in childhood lipid pneumonia following aspiration of animal fat. *Eur J Radiol*. 1993 Apr; 16(3):217-20.
- [6] Rabah R, Evans RW, Younis EJ. Mineral oil embolization and lipid pneumonia in an infant treated for Hirschsprung's disease. *Pediatr Pathol*. 1987; 7(4):447-55.
- [7] De la Rocha SR, Cunningham JC, Fox E. Lipid pneumonia secondary to baby oil aspiration: a case report and review of literature. *Pediatr Emerg Care*. 1985 Jun; 1(2):74-80.
- [8] Ciravegna B, Sacco O, Moroni C, et al. Mineral oil lipid pneumonia in a child with anoxic encephalopathy: treatment by whole lung lavage. *Pediatr Pulmonol*. 1997 Mar; 23(3):233-7.
- [9] Hari P. R. Bandla, Scott H, Hopkins N. Lipid Pneumonia: A Silent Complication of Mineral Oil Aspiration. *Pediatrics*. 1999; 103(2): e19.
- [10] Ayvazian LF, Steward DS, Merkel CG, Frederick WW. Diffuse lipid pneumonitis successfully treated with prednisone. *Am J Med*. 1967 Dec; 43(6):930-4.
- [11] Fan LL, Graham LR. Radiological case of the month. Lipid pneumonia from mineral oil aspiration. *Arch Pediatr Adolesc Med*. 1994 Feb; 148(2):205-6.
- [12] Cox EG, Heil SA, Kleiman MB. Lipid pneumonia and *Mycobacterium smegmatis*. *Pediatr Infect Dis J*. 1994 May; 13(5): 414-5.
- [13] Annobil SH, Benjamin B, Kameswaran M, Khan AR. Lipid pneumonia in children following aspiration of animal fat (ghee). *Ann Trop Paediatr*. 1991; 11(1):87-94.
- [14] Antico A, Gabrielli M, D'Aversa C, Musa M, Torri T. Lipid pneumonia: a case of cavitary bilateral nodular opacity. *Monaldi Arch Chest Dis*. 1996 Aug; 51(4):296-8.
- [15] Baron SE, Haramati LB, Rivera VT. Radiological and clinical findings in acute and chronic exogenous lipid pneumonia. *J Thorac Imaging*. 2003 Oct; 18(4): 217-24.
- [16] Joshi RR, Cholankeril JV. Computed tomography in lipid pneumonia. *J Comput Assist Tomogr*. 1985 Jan-Feb; 9(1):211-3.
- [17] Lee JS, Im JG, Song KS, Seo JB, Lim TH. Exogenous lipid pneumonia: high-resolution CT findings. *Eur Radiol*. 1999; 9(2): 287-91.

- [18] Lee KS, Muller NL, Hale V, Newell JD Jr, Lynch DA, Im JG. Lipoid pneumonia: CT findings. *J Comput Assist Tomogr*. 1995 Jan-Feb;19(1):48-51.
- [19] ~~E.S. Kim~~, ~~E.S. Kim~~, ~~K.W. Kim~~, ~~T.W. Song~~, ~~T.W. Song~~, ~~S.H. Cho~~, ~~S.H. Cho~~, ~~M. Kim~~, ~~M. Kim~~, ~~K. Kim~~, *et al.* Squalene-induced exogenous lipid pneumonia in an infant. *Pediatr Int*, 51 (5) (2009), pp. 751-753
- [20] ~~V. Hadda~~, ~~V. Hadda~~, ~~G.C. Khilnani~~, ~~G.C. Khilnani~~, Lipoid pneumonia: an ~~overview~~ ~~overview~~. *Expert Rev Respir Med*, 4 (6) (2010), pp. 799-807
- [21] Betancourt SL, Martinez-Jimenez S, Rossi SE, Truong MT, Carrillo J, Erasmus JJ. Lipoid pneumonia: spectrum of clinical and radiologic manifestations. *Am J Roentgenol*. 2010;194(1): 103-109.
- [22] Griese M, . Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. *Pediatrics*. 2017; 140(2): e20170610.
- [23] Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. *Nat Rev Dis Primers*. 2019; 5(1):16.
- [24] ~~LY BA Aïssata~~, ~~LY BA Aïssata~~, ~~LY Fatou~~, ~~LY Fatou~~, ~~BA Idrissa Demba~~, ~~BA Idrissa Demba~~, ~~DIAGNE Guilaye~~, ~~DIAGNE Guilaye~~, ~~THIAM Sokhna Astou Gawane~~, ~~THIAM Sokhna Astou Gawane~~, ~~DIOP Cheikh Tidiane~~, ~~DIOP Cheikh Tidiane~~, ~~DIOUF Papa Malick Dabor~~, ~~DIOUF Papa Malick Dabor~~, ~~TALL FALL Fatime~~, ~~TALL FALL Fatime~~, ~~CAMARA Boubacar~~, ~~CAMARA Boubacar~~, ~~N'DIAYE Ousmane et al.~~, Exogenous lipid pneumonia in infants ~~with suffering from~~ Hirschsprung's disease: radiographic and CT aspects. *J Afr Imag Méd* ~~2020~~ ~~2021~~; 12(4):243-248.